Gambogic acid impairs tumor angiogenesis by targeting YAP/STAT3 signaling axis

Area of Science:

• Molecular Biology
• Oncology
• Biochemistry

Background:

• Angiogenesis, the formation of new blood vessels, is crucial in physiological processes and pathological conditions like cancer.
• Tumor angiogenesis is a key target for anti-cancer therapies.
• Yes-associated protein (YAP) is a transcriptional factor regulating angiogenesis factors, making it a focus for anti-angiogenic therapy.

Purpose of the Study:

• To identify and characterize novel inhibitors of YAP.
• To evaluate the anti-angiogenic and anti-tumor effects of gambogic acid (GA).
• To elucidate the mechanism of action of GA in targeting the YAP/STAT3 signaling axis.

Main Methods:

• In vitro assays assessing endothelial cell proliferation, migration, sprouting, and tube formation.
• In vivo studies using Matrigel plugs in mice and chick chorioallantoic membrane assays.
• Tumor growth inhibition assays and mechanistic studies on the YAP/STAT3 signaling pathway.

Main Results:

• Gambogic acid (GA) significantly inhibited vascular endothelial growth factor-induced angiogenesis in vitro.
• GA reduced neovascularization in vivo and limited tumor growth by preventing tumor angiogenesis and vascular maturation.
• Mechanistic studies revealed that GA directly targets the YAP/STAT3 signaling axis.

Conclusions:

• Gambogic acid (GA) demonstrates potent anti-angiogenic and anti-tumor properties.
• GA acts by inhibiting the YAP/STAT3 signaling pathway, crucial for regulating angiogenic factors.
• These findings position GA as a promising drug candidate for cancer therapy.